These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30735565)

  • 1. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
    Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
    Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Intraocular Pressure Lowering Effect of a Dual Kinase Inhibitor (ITRI-E-(S)4046) in Ocular Hypertensive Animal Models.
    Chen YH; Lin WY; Huang YC; Ho WY; Fu CW; Tu CM; Hwang CS; Hung CL; Lin MC; Cheng F; Wang YJ; Chen CH; Chou SH; She MP; Yang CY; Cheng HL; Liu CP; Lu DW
    Invest Ophthalmol Vis Sci; 2021 Oct; 62(13):12. PubMed ID: 34661609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.
    Van de Velde S; Van Bergen T; Sijnave D; Hollanders K; Castermans K; Defert O; Leysen D; Vandewalle E; Moons L; Stalmans I
    Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1006-16. PubMed ID: 24474276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
    Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
    Curr Eye Res; 2014 Aug; 39(8):813-22. PubMed ID: 24502505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.
    Terao E; Nakakura S; Fujisawa Y; Fujio Y; Matsuya K; Kobayashi Y; Tabuchi H; Yoneda T; Fukushima A; Kiuchi Y
    Curr Eye Res; 2017 May; 42(5):738-742. PubMed ID: 27911106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma.
    Pakravan M; Beni AN; Ghahari E; Varshochian R; Yazdani S; Esfandiari H; Ahmadieh H
    Am J Ther; 2017; 24(6):e676-e680. PubMed ID: 26825486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.
    Prasanna G; Ferrara L; Adams C; Ehara T; Li B; Yang L; Xiang C; Ng CTH; Kim S; Towler C; Topley T; McAllister C; Ghosh M; Newton R; Stacy R; Rice DS; Mogi M
    Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1704-1716. PubMed ID: 29610853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.
    Savinainen A; Prusakiewicz JJ; Oswald J; Spencer E; Lou Z; Cohen ML; Rashidzadeh H; Josiah S
    Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.
    Lin CW; Sherman B; Moore LA; Laethem CL; Lu DW; Pattabiraman PP; Rao PV; deLong MA; Kopczynski CC
    J Ocul Pharmacol Ther; 2018; 34(1-2):40-51. PubMed ID: 28609185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    JAMA Ophthalmol; 2013 Oct; 131(10):1288-95. PubMed ID: 23787820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
    Kopczynski CC; Heah T
    Drugs Today (Barc); 2018 Aug; 54(8):467-478. PubMed ID: 30209441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
    Williams RD; Novack GD; van Haarlem T; Kopczynski C;
    Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes.
    Nishio M; Fukunaga T; Sugimoto M; Ikesugi K; Sumi K; Hidaka H; Uji Y
    Curr Eye Res; 2009 Apr; 34(4):282-6. PubMed ID: 19373576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits.
    Toris CB; McLaughlin MA; Dworak DP; Fan S; Havens S; Zhan GL; Horan N; Prasanna G
    J Ocul Pharmacol Ther; 2016; 32(6):355-64. PubMed ID: 27266531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
    Honjo M; Tanihara H
    Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
    Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading.
    Fukunaga T; Ikesugi K; Nishio M; Sugimoto M; Sasoh M; Hidaka H; Uji Y
    Curr Eye Res; 2009 Jan; 34(1):42-7. PubMed ID: 19172469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma.
    Skaat A; Jasien JV; Ritch R
    J Glaucoma; 2016 Sep; 25(9):e807-14. PubMed ID: 27552517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.